Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03769129
Recruitment Status : Recruiting
First Posted : December 7, 2018
Last Update Posted : December 7, 2018
Sponsor:
Information provided by (Responsible Party):
Second Affiliated Hospital of Guangzhou Medical University

Brief Summary:
This is a prospective, randomized, single clinical study designed to evaluate its safety and efficacy by using Microwave Ablation combine with Pembrolizumab in patients with Stage ⅢB-Ⅳ Non-small Cell Lung.Cancer (NSCLC) who failed with first-line therapy.

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer Drug: Pembrolizumab Procedure: microwave ablation Not Applicable

Detailed Description:

Lung cancer is one of the most common malignant tumors in the world and has become the No. 1 cause of death from malignant tumors in China. Non-small cell lung cancer (NSCLC) includes squamous cell carcinomas, adenocarcinomas, and large cell carcinomas and accounts for about 80-85% of all lung cancers. NSCLC cancer cells divide slowly in a diffusive manner and metastasize at a relatively late stage compared to small cell carcinomas. A majority of patients with NSCLC are already in advanced stages and have a low 5-year survival rate.

Treatments for advanced NSCLC include chemotherapy ,targeted therapies and immunotherapy. The microwave ablation is the good choice for patients who cannot tolerate surgical resection. A large number of studies have shown that local minimally invasive ablation therapy within a certain temperature range can stimulate the body to produce an immune response to varying degrees. The study found that for a variety of malignant tumor models, thermal ablation local treatment of in situ tumors, while the disappearance of other metastatic lesions, and treated mice are resistant to secondary vaccination of the same tumor, proving that thermal ablation therapy stimulates long-lasting Anti-tumor immunity. Pembrolizumab are representative drugs for immunosuppressive agents, and its indications have been approved in various types of tumors, including advanced melanoma, advanced squamous non-small cell lung cancer, advanced renal cell carcinoma, and classical Hodgkin's lymphoma and late recurrent head and neck squamous cell carcinoma patients. Whether the combination of the two can cause a stronger anti-tumor immune response in the body. However, the flexibility, safety and efficacy of using Microwave Ablation combine with Pembrolizumab in NSCLC patients are still unclear.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective ,Single Center, Randomized Control,III Phase Clinical Study for Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Patients With Stage ⅢB-Ⅳ NSCLC Who Failed With First-line Therapy
Actual Study Start Date : November 1, 2018
Estimated Primary Completion Date : November 1, 2020
Estimated Study Completion Date : November 1, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Microwave ablation
Firstly, microwave ablation performed at our department by interventional radiologist, then Pembrolizumab will be administered at a dose of 2 mg/kg every three weeks.
Drug: Pembrolizumab
Pembrolizumab
Other Name: Keytruda

Procedure: microwave ablation
microwave ablation

Pembrolizumab
Firstly, pembrolizumab was administered intravenously at a dose of 2 mg/kg. Then microwave ablation will be performed if there is no immune-related adverse reactions. Pembrolizumab will also be continuously administered every three weeks until the imaging evaluation of the disease progress.
Drug: Pembrolizumab
Pembrolizumab
Other Name: Keytruda

Procedure: microwave ablation
microwave ablation




Primary Outcome Measures :
  1. Overall survival [ Time Frame: 2 years ]
    Overall survival (OS) will be defined as the elapsed time from the enrollment to death from any cause. For surviving patients, follow-up will be censored at the date of last contact (or last date known to be alive). Follow-up for OS will occur every 12 weeks (±1 month) until death or withdrawal of consent from the study.


Secondary Outcome Measures :
  1. Incidence of Treatment-Emergent Adverse Events(Safety) [ Time Frame: 2 years ]
    All the local reactions, systemic reactions, all the adverse events and serious adverse events obtained during the study of all the patients included in the first stage and the second stage of this study

  2. Progression-Free Survival [ Time Frame: 2 years ]
    From enrollment to progression of disease.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Pathologically diagnosed IIIB or IV non-small cell lung cancer.
  2. Previously accepted first-line standard treatment failure or recurrence
  3. At least one measurable lesion.
  4. The patient has not received any other anti-cancer treatment within four weeks.
  5. Any gender, age ≥18 years
  6. ECOG PS : 0-2 points
  7. Expected survival ≥ 6 months
  8. The level of organ function meets the following criteria.

(1) subject to the standard blood test: ANC ≥ 1.5×109 / L, PLT ≥ 50×109 / L, Hb ≥ 90g/L.

(2) biochemical tests must meet the following criteria: TBIL<1.5×ULN, ALT, AST <2.5×ULN ( if liver metastasis ALT, AST can be <5×ULN), BUN, and Cr ≤ 1×ULN).

9. Female patients in child bearing period must have evidence of negative pregnancy test, and agree to take effective contraceptive measures until 6months after therapy.

10. Subjects volunteered to join the study, signed informed consent, good compliance, with follow-up.

Exclusion Criteria:

  1. Patients with two or more kinds of tumors.
  2. Patients with active viral or bacterial infection, and have failed to be controlled by anti-infective treatment.
  3. Patients with seropositive response of Human immunodeficiency virus (HIV) and syphilis, or fail to control the hepatitis B virus or hepatitis C virus infection.
  4. Patients with active rheumatic diseases, organ transplantation and other diseases affecting the immune system seriously.
  5. Patients with severe heart and lung dysfunction.
  6. Patients with severe chronic diseases of kidney, liver and other important organs.
  7. Patients with any other serious illness that the investigators consider it will may affect the patient's treatments, follow-up or assessment, including any uncontrolled clinically significant neurological or psychiatric disorders, immunoregulatory diseases, metabolic diseases, infectious diseases and so on.
  8. Patients who take part in clinical trials of other drugs or biological therapy at present or within 30 days before enrollment.
  9. Patients who need long-term use of immunosuppressive drugs or patients who are undergoing treatment of autoimmune diseases.
  10. Patients who need long-term use of glucocorticoid.
  11. Women patients in gestation period or suckling period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03769129


Contacts
Layout table for location contacts
Contact: zhang zhenfeng, MD,PHD 02034153532 zhangzhf@gzhmu.edu.cn
Contact: CHEN deji, MD,PHD 02034153532 chendeji2003@163.com

Locations
Layout table for location information
China, Guangdong
zhang Zhenfeng Recruiting
Guangzhou, Guangdong, China
Contact: Zhang Zhenfeng    13202005598    zhangzhf@gzhmu.edu.cn   
Sponsors and Collaborators
Second Affiliated Hospital of Guangzhou Medical University
Investigators
Layout table for investigator information
Principal Investigator: zhang zhenfeng, MD,PHD Second Affiliated Hospital of Guangzhou Medical University

Layout table for additonal information
Responsible Party: Second Affiliated Hospital of Guangzhou Medical University
ClinicalTrials.gov Identifier: NCT03769129     History of Changes
Other Study ID Numbers: Keytruda and MWA for NSCLC
First Posted: December 7, 2018    Key Record Dates
Last Update Posted: December 7, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Don not plan

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Second Affiliated Hospital of Guangzhou Medical University:
Microwave ablation
Pembrolizumab
NSCLC

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents